Q-omics provides the consensus-scored TNFSF12-TNFSF13 profile across patient tissues and cancer cell-line models. TNFSF12-TNFSF13 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TNFSF12-TNFSF13 is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, TNFSF12-TNFSF13 RNA expression shows 11,749 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where TNFSF12-TNFSF13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TNFSF12-TNFSF13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TNFSF12-TNFSF13 survival associations across molecular data types. TNFSF12-TNFSF13 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TNFSF12-TNFSF13 RNA expression–survival associations across cancer types. High TNFSF12-TNFSF13 expression shows unfavorable associations in ACC, MESO, LGG and LIHC, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for TNFSF12-TNFSF13 RNA expression.
This table summarizes TNFSF12-TNFSF13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for TNFSF12-TNFSF13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TNFSF12-TNFSF13 shows lower tumor expression in KICH, LUSC and BRCA and higher tumor expression in KIRC, KIRP and CHOL. The KIRC box plot shows higher TNFSF12-TNFSF13 RNA expression in tumor versus normal tissue (log2 FC = +0.139, t-test p < 0.001).
This table shows molecular features associated with TNFSF12-TNFSF13 in patient tissues and cancer cell lines. In patient samples, TNFSF12-TNFSF13 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TNFSF12-TNFSF13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Myeloma.
